Biomarkers predictive of predisposition to depression and response to treatment

Abstract

The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject's responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.

1 - 8 . (canceled) 
     
     
         9 . A method comprising detecting, in a sample obtained from a subject, the levels of expression products for a panel of multiple biomarkers, wherein the panel of multiple biomarkers comprises one or more of DGKA, KIAA1539, and RAPH1. 
     
     
         10 . (canceled) 
     
     
         11 . A method comprising detecting, in a sample obtained from a subject, the levels of expression products for a panel of multiple biomarkers, wherein the panel of multiple biomarkers comprises one or more of RAPH1, PSME1, IGSF4A, ADCY3, FAM46A and DGKA. 
     
     
         12 - 13 . (canceled) 
     
     
         14 . A method comprising detecting, in a sample obtained from a subject, the levels of expression products for a panel of multiple biomarkers, wherein the panel of multiple biomarkers comprises one or more of RAPH1, DRD2, OSBPL2, DAG1, OTX2, DPPA3, RAB27B, CTTNBP2, LIX1, NTRK2, SLC24A4, MARCKS, ASAH1, ATP11C, KIAA1539, and PSME1. 
     
     
         15 . The method of  claim 14 , wherein the panel of multiple biomarkers comprises one or more of ASAH1, ATPC11C, KIAA1539, MARCKS and PSME1. 
     
     
         16 . The method of  claim 9 , wherein the expression products are mRNAs corresponding to the biomarkers of the panel. 
     
     
         17 . The method of  claim 16 , wherein detecting the levels of expression products comprises exposing the sample to nucleic acid probes complementary to the mRNAs corresponding to the biomarkers of the panel. 
     
     
         18 . The method of  claim 17 , wherein the nucleic acid probes are covalently linked to a solid surface. 
     
     
         19 . The method of  claim 16 , wherein detecting the levels of expression products comprises use of a detection technique selected from the group consisting of microarray analysis, reverse transcriptase PCR, quantitative reverse transcriptase PCR, digital reverse transcriptase PCR and hybridization analysis. 
     
     
         20 . The method of  claim 9 , wherein the expression products are proteins corresponding to the biomarkers of the panel. 
     
     
         21 . The method of  claim 20 , wherein detecting the levels of expression products comprises exposing the sample to antibodies for the proteins corresponding to the biomarkers of the panel. 
     
     
         22 . The method of  claim 21 , wherein the antibodies are covalently linked to a solid surface. 
     
     
         23 . The method of  claim 20 , wherein detecting the levels of expression products comprises exposing the sample to a mass analysis technique. 
     
     
         24 - 39 . (canceled)